Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. (Q51613418)

8 April 2018

title

Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. (English)

1 reference

8 April 2018

1 reference

9

1 reference

8 April 2018

Yung-Jue Bang

11

object named as

Yung-Jue Bang

1 reference

8 April 2018

author name string

Huali Wu

1

1 reference

8 April 2018

Ramesh K Ramanathan

2

1 reference

8 April 2018

Beth A Zamboni

3

1 reference

8 April 2018

Sandra Strychor

4

1 reference

8 April 2018

Suresh Ramalingam

5

1 reference

8 April 2018

Robert P Edwards

6

1 reference

8 April 2018

David M Friedland

7

1 reference

8 April 2018

Ronald G Stoller

8

1 reference

8 April 2018

Lauren J Maruca

10

1 reference

8 April 2018

William C Zamboni

12

1 reference

8 April 2018

publication date

1 February 2012

1 reference

8 April 2018

The Journal of Clinical Pharmacology

published in

1 reference

8 April 2018

volume

52

1 reference

8 April 2018

issue

2

1 reference

8 April 2018

page(s)

180-194

1 reference

8 April 2018

Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Liposomal anthracycline treatment for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Use of liposomal anthracyclines in Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Concept and clinical evaluation of carrier-mediated anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Topoisomerase I interactive drugs in children with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Liposomal, nanoparticle, and conjugated formulations of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Drug delivery systems: entering the mainstream

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Pharmacokinetics of vinorelbine in patients with liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

Macrophage populations in different stages of induced hepatic metastases in rats: an immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010394851

21 January 2018

Identifiers

DOI

10.1177/0091270010394851

1 reference

8 April 2018

1 reference

8 April 2018